(Q47895451)

English

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects

scientific article published on 4 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Patricia N Sidharta

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

Paul L M van Giersbergen

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

Jasper Dingemanse

3

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

publication date

4 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

53

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

11

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

1131-1138

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Endothelin receptor antagonists in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Pharmacotherapeutic management of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Inflammatory responses of airway smooth muscle cells and effects of endothelin receptor antagonism.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Endothelin receptor antagonists for the treatment of pulmonary artery hypertension

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Molecular cloning and characterization of the murine bile salt export pump

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Transaminase elevation on placebo during phase I trials: prevalence and significance

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Drugs as CYP3A probes, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.152

21 January 2018

Identifiers

10.1002/JCPH.152

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/23900878

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47895451&oldid=2175007195"